“As administrations change, federal agencies’ leadership often changes to align with the incoming president’s priorities,” ...

Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned.  ...

Volta Medical put forward new data showing its artificial intelligence-guided ablation procedures were able to improve ...

A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...

After its depression candidate failed a phase 3 trial and disappointed analysts, Neumora is shaking up its leadership team.

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...

Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...

Otsuka has dumped a clutch of clinical cancer candidates on Valentine's day. | Otsuka has broken up with a clutch of clinical ...

Roche’s U.S. biotech subsidiary Genentech has wiped its website of past diversity reports as the company’s diversity and ...

Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...

While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...